Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant)

Abstract

Substantial survival benefits exist for patients with early-stage breast cancer who undergo treatment with single-modality ovarian suppression, but its value is uncertain. Expert oncologist discussed to determine whether additional benefits exist with ovarian suppression plus multiple adjuvant therapy which provides a new treatment option that reduces the risk of recurrence in early breast cancer. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.

Keywords

• AI
• exemestane
• LHRH agonist
• menopausal status
• monitoring
• tamoxifen